130369-04-9

Basic information

• Product Name: Carbamic acid, (3-methylenecyclobutyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (3-methylenecyclobutyl)-, 1,1-dimethylethyl ester (9CI);N-Boc-3-methylene-cyclobutanamine;CarbaMic acid, N-(3-Methylenecyclobutyl)-, 1,1-diMethylethyl ester;1-(Boc-amino)-3-methylenecyclobutane;tert-butyl (3-methylidenecyclobutyl)carbamate;(3-Methylenecyclobutyl)carbamic acid 1,1-dimethylethyl ester;tert-Butyl (3-methylenecyclobutyl)
• CAS NO: 130369-04-9
• Molecular Formula: C₁₀H₁₇NO₂
• Molecular Weight: 183.24748
• Product Categories: N-BOC
• Mol File: 130369-04-9.mol
• Article Data: 19

Chemical Properties

• Melting Point: 95-100°C
• Boiling Point: 263.8 °C at 760 mmHg
• Flash Point: 113.3 °C
• Appearance: /
• Density: 1 g/cm³
• Refractive Index: 1.474
• PKA: 12.22±0.20(Predicted)
• CAS DataBase Reference: Carbamic acid, (3-methylenecyclobutyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (3-methylenecyclobutyl)-, 1,1-dimethylethyl ester (9CI)(130369-04-9)
• EPA Substance Registry System: Carbamic acid, (3-methylenecyclobutyl)-, 1,1-dimethylethyl ester (9CI)(130369-04-9)

Safety Data

• Hazard Codes: N
• Statements: 50
• Safety Statements: 61
• RIDADR: UN 3077 9 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 130369-04-9(Hazardous Substances Data)

Usage

General Description

The chemical compound Carbamic acid, (3-methylenecyclobutyl)-, 1,1-dimethylethyl ester (9CI) is an ester of carbamic acid with a specific chemical structure. It is also known by its IUPAC name tert-butyl (1-methylethenecyclobutyl)carbamate. Carbamic acid, (3-methylenecyclobutyl)-, 1,1-dimethylethyl ester (9CI) is a colorless liquid with a molecular formula of C10H17NO2 and a molecular weight of 183.25 g/mol. It is commonly used in the synthesis of pharmaceuticals and agrochemicals due to its potential for use as an intermediate in organic chemical reactions. Carbamic acid, (3-methylenecyclobutyl)-, 1,1-dimethylethyl ester (9CI) is also used in laboratory research and may have other industrial applications. Additionally, it is important to handle carbamic acid, (3-methylenecyclobutyl)-, 1,1-dimethylethyl ester (9CI) with care and according to proper safety guidelines due to its potential hazards.

InChI:InChI=1/C10H17NO2/c1-7-5-8(6-7)11-9(12)13-10(2,3)4/h8H,1,5-6H2,2-4H3,(H,11,12)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 15760-36-8 3-methylenecyclobutane-1-carboxylic acid 
• 154748-49-9 3-(tert-butyloxycarbonylamino)cyclobutan-1-one 
• 1779-49-3 Methyltriphenylphosphonium bromide 
• 75-65-0 tert-butyl alcohol 
• 6399-81-1 triphenylphosphine hydrobromide 
• 15760-35-7 3-methylenecyclobutanecarbonitrile 
• 100114-49-6 3-methylenecyclobutylamine 

Downstream Products

• 1420270-95-6 tert-Butyl spiro[2.3]hexan-5-ylcarbamate 
• 1392803-14-3 tert-butyl (trans-3-aminocyclobutyl)methylcarbamate 
• 1033718-11-4 cis-3-[(tert-butoxycarbonyl)(methyl)amino]cyclobutyl methanesulfonate 
• 154748-63-7 tert-butyl ((1s,3s)-3-hydroxycyclobutyl)carbamate 
• 1427329-27-8 (3-hydroxy-3-methyl-cyclobutyl)-carbamic acid tert-butyl ester 
• 154748-49-9 3-(tert-butyloxycarbonylamino)cyclobutan-1-one 

Relevant articles and documents

1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS

A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Tigecycline derivatives (by machine translation)

The invention belongs to the medicinal technical field, and in particular relates to a tigecycline derivative of general formula (I), a pharmaceutically acceptable salt, precursor drug, solvate or isomer thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R

Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds.